Molecular testing in myelodysplastic syndromes for the practicing oncologist: Will the progress fulfill the promise?

Oncologist

Volumn 20, Issue 9, 2015, Pages 1069-1076

  Nazha, Aziz ^a   Sekeres, Mikkael A ^a   Gore, Steven D ^b   Zeidan, Amer M ^b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

Biomarkers; MDS; Molecular testing; Mutations; Myelodysplastic syndromes; Prognostication

Indexed keywords

BIOLOGICAL MARKER; TRANSCRIPTOME;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL PRACTICE; CYTOGENETICS; DNA SEQUENCE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; JUVENILE MYELOMONOCYTIC LEUKEMIA; MYELODYSPLASTIC SYNDROME; NEXT GENERATION SEQUENCING; ONCOLOGIST; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; RISK; RNA SPLICING; SOMATIC MUTATION; DISEASE COURSE; GENETICS; GENOMICS; MYELODYSPLASTIC SYNDROMES; PROCEDURES; PROGNOSIS;

DISEASE PROGRESSION; GENOMICS; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 84940659678     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0067     Document Type: Article

References (94)

1. Garcia-Manero G. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014;89:97-108
2. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009;361:1872-1885
3. Cazzola M, Della Porta MG, Travaglino E et al. Classification and prognostic evaluation of myelodysplastic syndromes. Semin Oncol 2011;38:627-634
4. Vardiman JW, Thiele J, Arber DA et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009;114:937-951
5. Bejar R, Stevenson K, Abdel-Wahab O et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364:2496-2506
6. Papaemmanuil E, Gerstung M, Malcovati L et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013; 122:3616-3627; quiz 3699
7. Haferlach T, Nagata Y, Grossmann V et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014;28: 241-247
8. Malcovati L, Papaemmanuil E, Ambaglio I et al. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood 2014;124:1513-1521
9. Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood 2013;122:4021-4034
10. Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860-921
11. Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science 2001;291: 1304-1351
12. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 2004;431:931-945
13. Lander ES. Initial impact of the sequencing of the human genome. Nature 2011;470:187-197
14. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 2012;489:57-74
15. Hansen TB, Jensen TI, Clausen BH et al. Natural RNA circles function as efficient microRNA sponges. Nature 2013;495:384-388
16. Bohlander SK. ABCs of genomics. Hematology. American Society of Hematology Education Pro-gram 2013;2013:316-323
17. Deeg HJ, Scott BL, Fang M et al. Fivegroup cytogenetic risk classification, monosomal karyo-type, and outcome after hematopoietic cell trans-plantation for MDS or acute leukemia evolving from MDS. Blood 2012;120:1398-1408
18. Haase D, Germing U, Schanz J et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients. Blood 2007; 110:4385-4395
19. Schanz J, Steidl C, Fonatsch C et al. Coalesced multicentric analysis of 2,351 patients with mye-lodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol 2011;29:1963-1970
20. Schanz J, Tüchler H, Solé F et al. New compre-hensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblas-ticacutemyeloidleukemiaafterMDSderivedfrom an international database merge. J Clin Oncol 2012;30:820-829
21. Caspersson T, Farber S, Foley GE et al. Chemical differentiation along metaphase chromosomes. Exp Cell Res 1968;49:219-222
22. Cazzola M, Malcovati L. Myelodysplastic syndromes: Coping with ineffective hematopoiesis. N Engl J Med 2005;352:536-538
23. Lindsley RC, Ebert BL. The biology and clinical impact of genetic lesions in myeloid malignancies. Blood 2013;122:3741-3748
24. Greenberg PL, Tuechler H, Schanz J et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454-2465
25. Coleman JF, Theil KS, Tubbs RR et al. Diagnostic yield of bone marrow and peripheral blood FISH panel testing in clinically suspected myelodysplastic syndromes and/or acute myeloid leukemia: A prospective analysis of 433 cases. Am J Clin Pathol 2011; 135:915-920
26. Maciejewski JP, Tiu RV, O’Keefe C. Application of arraybased whole genome scanning tech-nologies as a cytogenetic tool in haematological malignancies. Br J Haematol 2009;146:479-488
27. Maciejewski JP, Mufti GJ. Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood 2008;112:965-974
28. O’Keefe CL, Tiu R, Gondek LP et al. High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic syndromes. Exp Hematol 2007;35:240-251
29. Ahmad A, Iqbal MA. Significance of genome-wide analysis of copy number alterations and UPD in myelodysplastic syndromes using combined CGH-SNP arrays. Curr Med Chem 2012;19:3739-3747
30. Afable MG 2nd, Wlodarski M, Makishima H et al. SNP array-based karyotyping: Differences and similarities between aplastic anemia and hypocel-lular myelodysplastic syndromes. Blood 2011;117: 6876-6884
31. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977;74:5463-5467
32. Zagursky RJ, Berman ML. Cloning vectors that yield high levels of single-stranded DNA for rapid DNA sequencing. Gene 1984;27:183-191
33. Bentley DR, Balasubramanian S, Swerdlow HP et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature 2008; 456:53-59
34. Fu W, O’Connor TD, Jun G et al. Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. Nature 2013;493:216-220
35. Coffey AJ, Kokocinski F, Calafato MS et al. The GENCODE exome: Sequencing the complete human exome. Eur J Hum Genet 2011;19:827-831
36. Steijger T, Abril JF, Engström PG et al. Assessment of transcript reconstruction methods for RNA-seq. Nat Methods 2013;10:1177-1184
37. Djebali S, Davis CA, Merkel A et al. Landscape of transcription in human cells. Nature 2012;489: 101-108
38. Mortazavi A, Williams BA, McCue K et al. Mapping and quantifying mammalian transcrip-tomes by RNA-Seq. Nat Methods 2008;5:621-628
39. Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med 1997;336: 1365-1372
40. Gondek LP, DeZern AE. I walk the line: How to tell MDS from other bone marrow failure con-ditions. Curr Hematol Malig Rep 2014;9:389-399
41. Kulasekararaj AG, Jiang J, Smith AE et al. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. Blood 2014;124:2698-2704
42. Brian Kwok PR, Lin K, Flamholz R et al. Next-Generation Sequencing (NGS)-Based Profiling of Idiopathic Cytopenia of Undetermined Significance (ICUS) Identifies a Subset of Patients with Genomic Similarities to Lower-Risk Myelodysplastic Syndrome (MDS). Paper presented at: American Society of Hematology 56th Annual Meeting; December 6-9, 2014; San Francisco, CA
43. Cargo CNR, Evans P, Barrans S et al. Early Diagnosis of Myelodysplastic Syndromes Can be Improved By Deep Sequencing and Array Based Cytogenetics. Paper presented at: American Society of Hematology 56th Annual Meeting; December 6-9, 2014; San Francisco, CA
44. Jaiswal S, Fontanillas P, Flannick J et al. Age-related clonal hematopoiesis associated with ad-verse outcomes. N Engl J Med 2014;371:2488-2498
45. Genovese G, Kähler AK, Handsaker RE et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014;371: 2477-2487
46. Xie M, Lu C, Wang J et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 2014;20:1472-1478
47. McKerrell T, Park N, Moreno T et al. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Reports 2015; 10:1239-1245
48. Steensma DP, Bejar R, Jaiswal S et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 2015;pii
49. Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89: 2079-2088
50. Malcovati L, Germing U, Kuendgen A et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25: 3503-3510
51. Kantarjian H, O’Brien S, Ravandi F et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008;113:1351-1361
52. Zeidan AM, Gore SD, Padron E et al. Current state of prognostication and risk stratification in myelodysplastic syndromes. Curr Opin Hematol 2015;22:146-154
53. Faltas B, Zeidan A, Gergis U. Myelodysplastic syndromes: Toward a risk-adapted treatment ap-proach. Expert Rev Hematol 2013;6:611-624
54. Zeidan AM, Smith BD, Komrokji RS et al. Prognostication in myelodysplastic syndromes: Beyond the International Prognostic Scoring System (IPSS). Am J Med 2013;126:e25
55. Bejar R. Prognostic models in myelodysplastic syndromes. Hematology. American Society of He-matology Education Program 2013;2013:504-510
56. Lamarque M, Raynaud S, Itzykson R et al. The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: The GFM experience. Blood 2012;120:5084-5085
57. Sekeres MA, Swern AS, Fenaux P et al. Validation of the IPSS-R in lenalidomide-treated, lowerrisk myelodysplastic syndrome patients with del(5q). Blood Cancer J 2014;4:e242
58. Garcia-Manero G, Shan J, Faderl S et al. A prognostic score for patients with lower risk myelo-dysplastic syndrome. Leukemia 2008;22:538-543
59. Naqvi K, Jabbour E, Bueso-Ramos C et al. Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood 2011;118:4690-4693
60. Bejar R, Stevenson KE, Caughey BA et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodys-plastic syndromes. J Clin Oncol 2012;30:3376-3382
61. Itzykson R, Kosmider O, Renneville A et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013;31:2428-2436
62. Patnaik MM, Itzykson R, Lasho TL et al. ASXL1 and SETBP1 mutations and their prognostic contri-bution in chronic myelomonocytic leukemia: A twocenter study of 466 patients. Leukemia 2014;28: 2206-2212
63. Sekeres MA, Cutler C. How we treat higher-risk myelodysplastic syndromes. Blood 2014;123:829-836
64. Fenaux P, Ades L. Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes. Leuk Res 2009;33(suppl 2):S7-S11
65. List AF, Fenaux P, Mufti GJ et al. Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission. J Clin Oncol 2008;26:7006a
66. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al. Efficacy of azacitidine compared with that of conven-tional care regimens in the treatment of higherrisk myelodysplastic syndromes: A randomised, openlabel, phase III study. Lancet Oncol 2009;10: 223-232
67. Kantarjian H, Issa JP, Rosenfeld CS et al. Decitabine improves patient outcomes in myelodys-plastic syndromes: Results of a phase III randomized study. Cancer 2006;106:1794-1803
68. Kantarjian HM, O’Brien S, Huang X et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: Comparison with historical experience. Cancer 2007;109:1133-1137
69. Silverman LR, Fenaux P, Mufti GJ et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 2011;117:2697-2702
70. Gore SD, Hermes-DeSantis ER. Enhancing survival outcomes in the management of patients with higher-risk myelodysplastic syndromes. Cancer Control 2009;16(suppl):2-10
71. Gore SD, Fenaux P, Santini V et al. A multivariate analysis of the relationship between response and survival among patients with higherrisk myelodys-plastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica 2013;98:1067-1072
72. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 2008;123:8-13
73. Itzykson R, Kosmider O, Cluzeau T et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011;25: 1147-1152
74. Bejar R, Lord A, Stevenson K et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood 2014;124:2705-2712
75. Traina F, Visconte V, Elson P et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia 2014;28:78-87
76. Bejar R, Stevenson KE, Caughey B et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol 2014;32: 2691-2698
77. Bejar RPE, Haferlach T. TP53 mutation status divides MDS patients with complex karyotypes into distinct prognostic risk groups: Analysis of combined datasets from the International Working Group for MDS-Molecular Prognosis Committee. Blood 2014; 124:532a
78. Kulasekararaj AG, Smith AE, Mian SA et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol 2013;160:660-672
79. Saft L, Li JS, Greenberg PL et al. p53 mutant independently impacts risk: Analysis of deletion 5q, lower-risk myelodysplastic syndromes (MDS) patients treated with lenalidomide (LEN) in the MDS-004 Study. Blood 2014;124:414a
80. Zeidan AM, Komrokji RS. There’s risk, and then there’s risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes. Curr Hematol Malig Rep 2013;8:351-360
81. Dilsaver SC, DelMedico VJ, Quadri AB. Lithium-induced worsening of wintertime depression in a bipolar patient. J Clin Psychiatry 1990;51:347-348
82. Deshpande AJ, Bradner J, Armstrong SA. Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends Immunol 2012; 33:563-570
83. Stein EMAJ, Collins R et al. AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant metabolic enzyme, induces durable remissions in a phase I study in patients with IDH2 mutation positive advanced hematologic malignancies. Blood 2014;124:437[abstract 115]
84. Chaturvedi A, Araujo Cruz MM, Goparaju R et al. A novel inhibitor of mutant IDH1 induces differentiation in vivo and prolongs survival in a mouse model of leukemia. Blood 2014;124:3598a
85. Kon Kim T, Gore SD, Zeidan AM. Epigenetic therapy in acute myeloid leukemia: Current and future directions. Semin Hematol 2015;52:172-183
86. Valencia A, Masala E, Rossi A et al. Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. Leukemia 2014;28:621-628
87. Voso MT, Santini V, Fabiani E et al. Why methylation is not a marker predictive of response to hypomethylating agents. Haematologica 2014; 99:613-619
88. Zeidan AM, Lee JW, Prebet T et al. Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS. Brit J Haematol 2014;167:62-68
89. Meldi K, Qin T, Buchi F et al. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. J Clin Invest 2015;125: 1857-1872
90. Zeidan AM, Lee JW, Prebet T et al. Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes. Brit J Haematol 2014;166:352-359
91. Zeidan AM, Linhares Y, Gore SD. Current therapy of myelodysplastic syndromes. Blood Rev 2013;27:243-259
92. Zeidan AM, Prebet T, Saad Aldin E et al. Risk stratification in myelodysplastic syndromes: Is there a role for gene expression profiling? Expert Rev Hematol 2014;7:191-194
93. Lee EJ, Zeidan AM. Genome sequencing in myelodysplastic syndromes: can molecular muta-tions predict benefit from hypomethylating agent therapy? Expert Rev Hematol 2015;8:155-158
94. Lee EJ, Podoltsev N, Gore SD et al. The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions. Blood Rev 2015 [Epub ahead of print]